A proof of concept for structure-based vaccine design targeting RSV in humans

Crank, Michelle C., Ruckwardt, Tracy J., Chen, Man, Morabito, Kaitlyn M., Phung, Emily, Costner, Pamela J., Holman, LaSonji A., Hickman, Somia P. +43 more·2019·Science
DOI 10.1126/science.aav9033

Cited by (333)

Items 101–200 of 333

  1. Respiratory syncytial virus entry mechanism in host cells: A general overview
    Christian Cadena-Cruz, Jose Luis Villarreal Camacho, Marcio De-Ávila-Arias, Leidy Hurtado-Gómez, Alexander Rodríguez, Homero G. San-Juan-Vergara · 2023 · Molecular Microbiology
  2. MPLA-Adjuvanted Liposomes Encapsulating S-Trimer or RBD or S1, but Not S-ECD, Elicit Robust Neutralization Against SARS-CoV-2 and Variants of Concern
    Jian Wang, Xuguang Yin, Yu Wen, Jie Li Lu, Ruyan Zhang, Shihao Zhou, Chun-Miao Liao, Hua-Wei Wei, Jun Guo · 2022 · Journal of Medicinal Chemistry
  3. CAF08 adjuvant enables single dose protection against respiratory syncytial virus infection in murine newborns
    Simon D. van Haren, Gabriel Kristian Pedersen, Azad Kumar, Tracy J. Ruckwardt, Syed Mohammad Moin, Ian N. Moore, Mahnaz Minai, Mark Liu, Jensen Pak, Francesco Borriello et al. · 2022 · Nature Communications
  4. Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trial
    Chong Ma, Jiejun Du, Lan Lan, Archana Kapoor, Gonzalo Pérez Marc, Gilberto Jimenez, Christopher James Arthur Duncan, Nancy Le Cam, Nina Lin, Frances H. Priddy et al. · 2025 · Nature Communications
  5. Interprotomer disulfide-stabilized variants of the human metapneumovirus fusion glycoprotein induce high titer-neutralizing responses
    Guillaume B. E. Stewart-Jones, Jason Gorman, Li Ou, Baoshan Zhang, Michael Gordon Joyce, Lijuan Yang, Cheng Cheng, Gwo‐Yu Chuang, Kathryn E. Foulds, Wing‐Pui Kong et al. · 2021 · Proceedings of the National Academy of Sciences
  6. Innate Immune Response and Inflammasome Activation During SARS-CoV-2 Infection
    Mohammad Islamuddin, Salman Ahmad Mustfa, Shehla Nasar Mir Najib Ullah, Usmaan Omer, Kentaro Kato, Shama Parveen · 2022 · Inflammation
  7. Rational design of uncleaved prefusion-closed trimer vaccines for human respiratory syncytial virus and metapneumovirus
    Yi-Zong Lee, Jerome Han, Yi-Nan Zhang, Garrett Ward, Keegan Braz Gomes, Sarah Auclair, Robyn L. Stanfield, Linling He, Ian A. Wilson, Jiang Zhu · 2024 · Nature Communications
  8. RSV neutralization assays – Use in immune response assessment
    Rama Raghunandan, Deborah Higgins, Nancy A. Hosken · 2021 · Vaccine
  9. CHO cells for virus-like particle and subunit vaccine manufacturing
    Zalma V. Sanchez-Martinez, Sergio P. Alpuche‐Lazcano, Matthew Stuible, Yves Durocher · 2024 · Vaccine
  10. COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment – Meeting report from an isirv-WHO virtual conference
    Jennifer L. McKimm‐Breschkin, Alan J Hay, Bin Cao, Rebecca Jane Cox, Jake W Dunning, Ann C. Moen, Daniel Olson, Andrés Pizzorno, Frederick G. Hayden · 2021 · Antiviral Research
  11. A foldon-free prefusion F trimer vaccine for respiratory syncytial virus to reduce off-target immune responses
    Mark J. G. Bakkers, Freek Cox, Annemart Koornneef, Xiaodi Yu, Daan van Overveld, Lam Le, Ward van den Hoogen, Joost Vaneman, Anne Thoma, Richard Voorzaat et al. · 2024 · Nature Microbiology
  12. Vaccine and therapeutic agents against the respiratory syncytial virus: resolved and unresolved issue
    Qianqian Li, Huan Li, Zhihua Li, Youchun Wang · 2024 · MedComm
  13. Flexible RSV Prefusogenic Fusion Glycoprotein Exposes Multiple Neutralizing Epitopes that May Collectively Contribute to Protective Immunity
    Nita Patel, Jing-Hui Tian, Rhonda Flores, Kelsey Jacobson, Michelle Walker, Alyse D. Portnoff, Mimi Gueber-Xabier, Michael J. Massare, Greg M. Glenn, Larry R. Ellingsworth et al. · 2020 · Vaccines
  14. An overview of methods for the structural and functional mapping of epitopes recognized by anti-SARS-CoV-2 antibodies
    I. Francino-Urdaniz, T. Whitehead · 2021 · RSC Chemical Biology
  15. All Eyes on the Prefusion-Stabilized F Construct, but Are We Missing the Potential of Alternative Targets for Respiratory Syncytial Virus Vaccine Design?
    Sofie Schaerlaekens, Lotte Jacobs, Kim Stobbelaar, Paul Cos, Peter Delputte · 2024 · Vaccines
  16. A nanobody specific to prefusion glycoprotein B neutralizes HSV-1 and HSV-2
    Benjamin Vollmer, Henriette Ebel, Renate Rees, Julia Nentwig, Thomas Mulvaney, Jürgen Schünemann, Jens Krull, Maya Topf, Dirk Görlich, Kay Grünewald · 2025 · Nature
  17. Level of maternal respiratory syncytial virus (RSV) F antibodies in hospitalized children and correlates of protection
    Sara Taleb, Khalid Alansari, Gheyath K. Nasrallah, Mohamed A. Elrayess, Asmaa A. Al Thani, Alexandrine Derrien-Colemyn, Tracy J. Ruckwardt, Barney S. Graham, Hadi Mohamad Yassine · 2021 · International Journal of Infectious Diseases
  18. Immunogenicity and protective efficacy of RSV G central conserved domain vaccine with a prefusion nanoparticle
    Jennifer N. Rainho-Tomko, Vincent Pavot, Michael Kishko, Kurt A. Swanson, Darin Edwards, Heesik Yoon, Lilibeth Lanza, Judith G. Alamares-Sapuay, Robert Osei-Bonsu, Sophia T. Mundle et al. · 2022 · npj Vaccines
  19. Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: Preclinical studies and Phase 1 clinical testing in healthy adults
    Jesse C. Nussbaum, Xin Cao, Radha A. Railkar, Jeffrey R. Sachs, Daniel S. Spellman, Julie Ann Mabalot Luk, Christine A. Shaw, Pedro Joel Cejas, Michael P. Citron, Mohamed S Al-Ibrahim et al. · 2023 · Vaccine
  20. The Impact of Vaccination on COVID-19, Influenza, and Respiratory Syncytial Virus-Related Outcomes: A Narrative Review
    Roberto Debbag, Deborah Rudin, Francesca Ceddia, John Watkins · 2024 · Infectious Diseases and Therapy
  21. A Single Shot Pre-fusion-Stabilized Bovine RSV F Vaccine is Safe and Effective in Newborn Calves with Maternally Derived Antibodies
    Sabine Riffault, Sara Hägglund, Efrain Guzman, Katarina Näslund, Luc Jouneau, Catherine Dubuquoy, Vincent Pietralunga, Daphné Laubreton, Olivier Boulesteix, David Gauthier et al. · 2020 · Vaccines
  22. A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters
    Mijia Lu, Yuexiu Zhang, Piyush Dravid, Anzhong Li, Cong Zeng, Mahesh KC, Sheetal Trivedi, Himanshu Sharma, Supranee Chaiwatpongsakorn, Ashley Zani et al. · 2021 · Journal of Virology
  23. Effects of Adjuvants on the Immunogenicity and Efficacy of a Zika Virus Envelope Domain III Subunit Vaccine
    Xinyi Wang, Wanbo Tai, Xiaolu Zhang, Yusen Zhou, Lanying Du, Chuanlai Shen · 2019 · Vaccines
  24. Vaccines to Overcome Antibiotic Resistance: The Challenge of Burkholderia cenocepacia
    Viola Camilla Scoffone, Giulia Barbieri, Silvia Buroni, Maria Scarselli, Mariagrazia Pizza, Rino Rappuoli, Giovanna Riccardi · 2020 · Trends in Microbiology
  25. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity
    M. Gordon Joyce, Wei-Hung Chen, Rajeshwer S. Sankhala, Agnes Hajduczki, Paul V. Thomas, Misook Choe, William Chang, Caroline E. Peterson, Elizabeth Martinez, Elaine B. Morrison et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  26. Restricted valency (NPNA)n repeats and junctional epitope-based circumsporozoite protein vaccines against Plasmodium falciparum
    Mark D. Langowski, Farhat A. Khan, Sofya Savransky, Dallas R. Brown, Arasu Balasubramaniyam, William B. Harrison, Xiaoyan Zou, Zoltán Beck, Gary R. Matyas, Jason A. Regules et al. · 2022 · npj Vaccines
  27. Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects
    Amitinder Kaur, Monica Vaccari · 2024 · Viruses
  28. Combinatorial F-G Immunogens as Nipah and Respiratory Syncytial Virus Vaccine Candidates
    Ariel Isaacs, Stacey T. M. Cheung, Nazia Thakur, Noushin Jaberolansar, Andrew Young, Naphak Modhiran, Dalan Bailey, Simon Paul Graham, Paul R. Young, Keith Joseph Chappell et al. · 2021 · Viruses
  29. Implications of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic on the Epidemiology of Pediatric Respiratory Syncytial Virus Infection
    Oludare A. Odumade, Simon D. van Haren, Asimenia Angelidou · 2022 · Clinical Infectious Diseases
  30. Double-Blind, Placebo-Controlled, Dose-Escalating Study Evaluating the Safety and Immunogenicity of an Epitope-Specific Chemically Defined Nanoparticle RSV Vaccine
    Isabel Leroux‐Roels, Jacques Bruhwyler, Lilli Stergiou, Mark S. Sumeray, Jasper Joye, Cathy Maes, Paul‐Henri Lambert, Geert G Leroux-Roels · 2023 · Vaccines
  31. A potential bivalent mRNA vaccine candidate protects against both RSV and SARS-CoV-2 infections
    Namei Wu, Jiachen Zhang, Yanqiong Shen, Xinghai Zhang, Jinge Zhou, Yan Wu, Entao Li, Xiao‐Ming Meng, Xia Chuai, Sandra Chiu et al. · 2024 · Molecular Therapy
  32. An epitope-specific chemically defined nanoparticle vaccine for respiratory syncytial virus
    Armando Zúñiga, Oliver Rassek, Melissa Vrohlings, Aniebrys Marrero, Kerstin Moehle, John A. Robinson, Arin Ghasparian · 2021 · npj Vaccines
  33. TIPICO IX: report of the 9th interactive infectious disease workshop on infectious diseases and vaccines
    Federico Martinón‐Torres, Xavier F. Bosch, Rino Rappuoli, Shamez N Ladhani, Esther Redondo, Timo Vesikari, Adolfo García‐Sastre, Irene Rivero Calle, José Gómez Rial, Antonio Salas et al. · 2019 · Human Vaccines & Immunotherapeutics
  34. RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models
    Freek Cox, Eiríkur Saeland, Anne Thoma, Ward van den Hoogen, Lisanne Tettero, Joke Drijver, Cornelis Vaneman, Yolinda van Polanen, Tina Ritschel, Arangassery Rosemary Bastian et al. · 2023 · Vaccines
  35. Immunogenicity of an AS01-adjuvanted respiratory syncytial virus prefusion F (RSVPreF3) vaccine in animal models
    Badiaa Bouzya, Ronan Nicolas Rouxel, Lionel Sacconnay, Romuald Mascolo, Laurence Nols, Stéphanie Quique, Loïc François, Anne Atas, Lucile Warter, Nancy Dezutter et al. · 2023 · npj Vaccines
  36. Correlating Stability-Indicating Biochemical and Biophysical Characteristics with In Vitro Cell Potency in mRNA LNP Vaccine
    Xin Tong, Jessica Raffaele, Katrina Feller, Geethanjali Dornadula, James Devlin, David Boyd, John W. Loughney, Jon Shanter, Richard R. Rustandi · 2024 · Vaccines
  37. Prokaryote- and Eukaryote-Based Expression Systems: Advances in Post-Pandemic Viral Antigen Production for Vaccines
    Nelli S. Khudainazarova, Dmitriy L. Granovskiy, Olga A. Kondakova, Ekaterina M. Ryabchevskaya, Angelina O. Kovalenko, Ekaterina A. Evtushenko, Marina V. Arkhipenko, Nikolai A. Nikitin, Olga V. Karpova · 2024 · International Journal of Molecular Sciences
  38. Virus-like particles containing a prefusion-stabilized F protein induce a balanced immune response and confer protection against respiratory syncytial virus infection in mice
    Jin Luo, Huan Qin, Lei Lei, Wange Lou, Ruitong Li, Zishu Pan · 2022 · Frontiers in Immunology
  39. Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein elicits antibodies targeting a membrane-proximal epitope
    Ryan S. McCool, Maryam Mukhamedova, Sabrina M. Bush, Alexandrine Derrien-Colemyn, Cory M. Acreman, Daniel Wrapp, Tracy J. Ruckwardt, Barney S. Graham, John R. Mascola, Jason S. McLellan · 2023 · Journal of Virology
  40. Quantification of mRNA in Lipid Nanoparticles Using Mass Spectrometry
    Mark S. Lowenthal, Abigail S. Antonishek, Karen W. Phinney · 2024 · Analytical Chemistry
  41. Sendai Virus-Vectored Vaccines That Express Envelope Glycoproteins of Respiratory Viruses
    Charles J. Russell, Julia L. Hurwitz · 2021 · Viruses
  42. Immunogenicity and protective efficacy of adenoviral and subunit RSV vaccines based on stabilized prefusion F protein in pre-clinical models
    Eiríkur Saeland, Leslie van der Fits, Renske Bolder, Marjolein Heemskerk-van der Meer, Joke Drijver, Yolinda van Polanen, Cornelis Vaneman, Lisanne Tettero, Jan Serroyen, Hanneke Schuitemaker et al. · 2021 · Vaccine
  43. Crystal Structure of RSV strain B18537 Prefusion-stabilized glycoprotein F Variant DS-Cav1
    Michael Gordon Joyce, Amy Bao, Peter D. Kwong · 2019 · Worldwide Protein Data Bank
  44. Recurrent Respiratory Syncytial Virus Infection in a CD14-Deficient Patient
    Sjanna B. Besteman, Emily Phung, Henriette H. M. Raeven, Gimano D. Amatngalim, Matevž Rumpret, Juliet Crabtree, Rutger M. Schepp, Lisa W. Rodenburg, Susanna G Siemonsma, Nile Verleur et al. · 2022 · The Journal of Infectious Diseases
  45. Accelerating clinical trial development in vaccinology: COVID-19 and beyond
    Lawrence Corey, Maurine D. Miner · 2022 · Current Opinion in Immunology
  46. An entropic safety catch controls hepatitis C virus entry and antibody resistance
    Lenka Stejskal, Mphatso D. Kalemera, Charlotte B. Lewis, Machaela Palor, Lucas M. Walker, Tina Daviter, William Lees, David S. Moss, Myrto Kremyda-Vlachou, Zisis Kozlakidis et al. · 2022 · eLife
  47. Universal paramyxovirus vaccine design by stabilizing regions involved in structural transformation of the fusion protein
    Johannes P. M. Langedijk, Freek Cox, Nicole V. Johnson, Daan van Overveld, Lam Le, Ward van den Hoogen, Richard Voorzaat, Roland C. Zahn, Leslie van der Fits, Jarek Juraszek et al. · 2024 · Nature Communications
  48. A Vulnerable, Membrane-Proximal Site in Human Respiratory Syncytial Virus F Revealed by a Prefusion-Specific Single-Domain Antibody
    Iebe Rossey, Ching‐Lin Hsieh, Koen Sedeyn, Marlies Ballegeer, Bert Schepens, Jason S. McLellan, Xavier Saelens · 2021 · Journal of Virology
  49. RCSB Protein Data Bank resources for structure-facilitated design of mRNA vaccines for existing and emerging viral pathogens
    David S. Goodsell, Stephen Kevin Burley · 2021 · Structure
  50. Respiratory Syncytial Virus Prefusion F Vaccination: Antibody Persistence and Revaccination
    Edward E. Walsh, Ann Regina Falsey, Agnieszka Zareba, Qin Li Jiang, Alejandra Gurtman, David R. Radley, Emily A. Gomme, David Cooper, Kathrin Ute Jansen, William C. Gruber et al. · 2024 · The Journal of Infectious Diseases
  51. Elicitation of pneumovirus-specific B cell responses by a prefusion-stabilized respiratory syncytial virus F subunit vaccine
    Emily Phung, Lauren A. Chang, Maryam Mukhamedova, Lijuan Yang, Deepika Nair, Scott A. Rush, Kaitlyn M. Morabito, Jason S. McLellan, Ursula J. Buchholz, John R. Mascola et al. · 2022 · Science Translational Medicine
  52. A robust pipeline for high-content, high-throughput immunophenotyping reveals age- and genetics-dependent changes in blood leukocytes
    Thomas Liechti, Sofie Van Gassen, Margaret H. Beddall, Reid B. Ballard, Yaser Iftikhar, Renguang Du, Thiagarajan Venkataraman, David Novák, Massimo Mangino, Stephen P. Perfetto et al. · 2023 · Cell Reports Methods
  53. A neutralizing single-domain antibody that targets the trimer interface of the human metapneumovirus fusion protein
    Marlies Ballegeer, Revina C. van Scherpenzeel, Teresa Delgado, María Iglesias‐Caballero, Blanca García‐Barreno, Shubham Pandey, Scott A. Rush, Joost A. Kolkman, Vicente Más, Jason S. McLellan et al. · 2023 · mBio
  54. Interactions Between Bovine Respiratory Syncytial Virus and Cattle: Aspects of Pathogenesis and Immunity
    Lariane da Silva Barcelos, Alexandra K. Ford, Matheus Iuri Frühauf, Nadálin Yandra Botton, Geferson Fischer, Mayara F. Maggioli · 2024 · Viruses
  55. Characterization of the SARS-CoV-2 Spike in an Early Prefusion Conformation
    Tingting Li, Qingbing Zheng, Hai Jing Yu, Dinghui Wu, Wenhui Xue, Yuyun Zhang, Xiaofen Huang, Lizhi Zhou, Zhigang Zhang, Zhenghui Zha et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  56. Convergent structural features of respiratory syncytial virus neutralizing antibodies and plasticity of the site V epitope on prefusion F
    Wayne D. Harshbarger, Sai Tian, Newton Wahome, Ankita Balsaraf, Deep S. Bhattacharya, Desheng Jiang, Ratnesh Pandey, Kunal Tungare, Kristian Friedrich, Nurjahan Mehzabeen et al. · 2020 · PLoS Pathogens
  57. Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein
    Wayne D. Harshbarger, Priyanka D. Abeyrathne, Sai Tian, Ying Huang, Sumana Chandramouli, Matthew J. Bottomley, E. Malito · 2021 · mAbs
  58. Viral informatics: bioinformatics-based solution for managing viral infections
    Sanjay Kumar, Geethu S Kumar, Subhrangsu Sundar Maitra, Petr Malý, Shiv Bharadwaj, Pradeep Sharma, Vivek Dhar Dwivedi · 2022 · Briefings in Bioinformatics
  59. Immunization with a Prefusion SARS-CoV-2 Spike Protein Vaccine (RBMRNA-176) Protects against Viral Challenge in Mice and Nonhuman Primates
    Qinhai Ma, Runfeng Li, Jianmin Guo, Man Li, Lin Ma, Jun Dai, Yongxia Shi, Jinlong Dai, Yuankeng Huang, Cailing Dai et al. · 2022 · Vaccines
  60. Development and qualification of cell-based relative potency assay for a human respiratory syncytial virus (RSV) mRNA vaccine
    Hualin Helen Li, Jenny Xu, He Li, Lynne Ireland Denny, Richard R. Rustandi, Geethanjali Dornadula, Brock Fiorito, Zhiqiang Zhang · 2023 · Journal of Pharmaceutical and Biomedical Analysis
  61. Global progress in clinical research on human respiratory syncytial virus vaccines
    Ruofan Peng, Chenghao Chen, Qian Chen, Yuwen Zhang, Renjin Huang, Yanjun Zhang, Jianhua Li · 2024 · Frontiers in Microbiology
  62. Human monoclonal antibodies for discovery, therapy, and vaccine acceleration
    Emanuele Andreano, Anja Seubert, Rino Rappuoli · 2019 · Current Opinion in Immunology
  63. Development of prime–boost-type next-generation mucosal vaccines
    Kosuke Fujimoto, Satoshi Uematsu · 2019 · International Immunology
  64. Respiratory Syncytial Virus Infections in Neonates: A Persisting Problem
    Akhil Maheshwari, Srijan Singh, Ilhama Namazova, John T. Benjamin, Yuping Wang · 2023 · Newborn
  65. Respiratory Syncytial Virus Vaccines: Analysis of Pre-Marketing Clinical Trials for Immunogenicity in the Population over 50 Years of Age
    Georgios Papazisis, Xanthippi Topalidou, Georgia Gioula, Pablo A. González, Susan M. Bueno, Alexis M. Kalergis · 2024 · Vaccines
  66. Immunological drivers of zoonotic virus emergence, evolution, and endemicity
    Jyothi N. Purushotham, Holly L. Lutz, Edyth Parker, Kristian G. Andersen · 2025 · Immunity
  67. A morphological transformation in respiratory syncytial virus leads to enhanced complement deposition
    Jessica P. Kuppan, Margaret D. Mitrovich, Michael D. Vahey · 2021 · eLife
  68. High Throughput Designing and Mutational Mapping of RBD-ACE2 Interface Guide Non-Conventional Therapeutic Strategies for COVID-19
    Aditya Kumar Padhi, Parismita Kalita, Kam Y. J. Zhang, Timir Tripathi · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  69. Clinical validation of an RSV neutralization assay and analysis of cross-sectional sera associated with 2021–2023 RSV outbreaks to investigate the immunity debt hypothesis
    Eli A. Piliper, Jonathan C. Reed, Alexander L. Greninger · 2024 · Microbiology Spectrum
  70. Newly Emerging Human Coronaviruses: Animal Models and Vaccine Research for SARS, MERS, and COVID-19
    Pureum Lee, Doo-Jin Kim · 2020 · Immune Network
  71. Longitudinal study of the immune response and memory following natural bovine respiratory syncytial virus infections in cattle of different age
    Sara Hägglund, Katarina Näslund, Anna Christina Svensson, Cecilia Lefverman, Hakan Enül, Leonore Pascal, Jari Siltenius, M. Holzhauer, Alexis Delabouglise, Julia Österberg et al. · 2022 · PLoS ONE
  72. Precision vaccine design targeting the prefusion state of viral glycoproteins: advances in structural vaccinology
    Reetesh Kumar, Somnath Maji, Savitri Tiwari, J. P. Misra, Jyoti Gupta, Naveen Kumar, Rohan Gupta, Niraj Kumar Jha · 2025 · Biochemical Pharmacology
  73. VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice
    Benjamin Trinité, Eberhard Dürr, Anna Pons-Grífols, Gregory T. O’Donnell, Carmen Aguilar‐Gurrieri, Silveria Rodriguez, Víctor Urrea, Ferran Tarrés-Freixas, Joel Mane, Raquel Ortiz et al. · 2024 · Vaccine
  74. Preventing RSV Infection in Children: Current Passive Immunizations and Vaccine Development
    Pius I. Babawale, Iván Martínez-Espinoza, Alaine’ M. Mitchell, Antonieta Guerrero-Plata · 2025 · Pathogens
  75. Respiratory syncytial virus: health burden, disease prevention, and treatment—recent progress and lessons learned
    Harald Brüssow · 2025 · microLife
  76. Design and preclinical assessment of mRNA-1345 prefusion F glycoprotein-encoding mRNA vaccine for respiratory syncytial virus
    Christine A. Shaw, Guillaume B. E. Stewart-Jones, Patricia A. Jorquera, Elisabeth Narayanan, Sayda M. Elbashir, Paulina Kapłonek, LingZhi Ma, Naila Hunter, Erin Hanahoe, Tatiana Ketova et al. · 2025 · Vaccine
  77. Pharmacological management of human respiratory syncytial virus infection
    Alexis M. Kalergis, Jorge A. Soto, Nicolás M. S. Gálvez, Catalina A. Andrade, Ayleen Fernández‐Fierro, Karen Böhmwald, Susan M. Bueno · 2020 · Expert Opinion on Pharmacotherapy
  78. Up-to-date role of biologics in the management of respiratory syncytial virus
    Seyhan Boyoglu-Barnum, Ralph A. Tripp · 2020 · Expert Opinion on Biological Therapy
  79. The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice
    Longbo Hu, Yuhua Xu, Liping Wu, Jin Feng, Lu Zhang, Yongjie Tang, Xiang Zhao, Runming Mai, Liyun Chen, Lingling Mei et al. · 2022 · Viruses
  80. Regulatory perspective for quality evaluation of lipid nanoparticle-based mRNA vaccines in China
    Jiaqi Lu, Wei Wei, Wu He · 2023 · Biologicals
  81. Mutations in the F protein of the live-attenuated respiratory syncytial virus vaccine candidate ΔNS2/Δ1313/I1314L increase the stability of infectivity and content of prefusion F protein
    Judith G. Alamares-Sapuay, Michael Kishko, Charles Lai, Mark Parrington, Simon Delagrave, Richard L. Herbert, Ashley Castens, Joanna Swerczek, Cindy Luongo, Lijuan Yang et al. · 2024 · PLoS ONE
  82. Antibody responses to respiratory syncytial virus: a population-based cross-sectional serological study in Southern China, 2021
    Qianli Wang, Nuolan Liu, Yan Wang, Tracy J. Ruckwardt, Meng Xu, Jianan Wu, Juanjuan Zhang, Xiaofeng Tong, Jiaxin Zhou, Jiqun Lin et al. · 2024 · Clinical Microbiology and Infection
  83. A Randomized, Double‐Blind, Placebo‐Controlled, Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Single Vaccination of Ad26.RSV.preF‐Based Regimen in Japanese Adults Aged 60 Years and Older
    Takashi Eto, Yusuke Okubo, Atsushi Momose, Hiroshi Tamura, Richuan Zheng, Benoît Callendret, Arangassery Rosemary Bastian, Christy A. Comeaux · 2024 · Influenza and Other Respiratory Viruses
  84. Safety and immunogenicity of an mRNA-based RSV vaccine in Japanese older adults aged ≥60 years: A phase 1, randomized, observer-blind, placebo-controlled trial
    David Fitzpatrick, Hanako Mihara, Anthony Mills, Runa Mithani, Archana Kapoor, Rakesh Dhar, Lauren Wilson, Ruiting Guo, Alana K. Simorellis, Catherine A. Panozzo et al. · 2024 · Respiratory Investigation
  85. Highly scalable prefusion-stabilized RSV F vaccine with enhanced immunogenicity and robust protection
    Qiong-lian Huang, Qingyun Lang, Yao Li, Fengjie Wang, Xiaonan Han, Ling Luo, Xiaomin Duan, Xuerong Cao, Yue Wang, Yu Bai et al. · 2025 · Nature Communications
  86. Directed attenuation to enhance vaccine immunity
    Rustom Antia, Hasan Ahmed, James J. Bull · 2021 · PLoS Computational Biology
  87. Can early measles vaccination control both measles and respiratory syncytial virus infections?
    Lien Anh Ha Do, Zheng Quan Toh, Paul Vincent Licciardi, Edward Kim Mulholland · 2021 · The Lancet Global Health
  88. Vaccine development and technology for SARS‐CoV‐2: Current insight
    Luigi Cattel, Susanna Giordano, Sara Traina, Tommaso Lupia, Silvia Corcione, Lorenzo Angelone, Giovanni La Valle, Francesco Giuseppe De Rosa, Francesco Cattel · 2021 · Journal of Medical Virology
  89. SARS-CoV-2 Ferritin Nanoparticle Vaccines Elicit Broad SARS Coronavirus Immunogenicity
    Michael Gordon Joyce, Wei‐Hung Chen, Rajeshwer Singh Sankhala, Agnes Hajduczki, Paul V. Thomas, Misook Choe, Elizabeth J. Martinez, William C. Chang, Caroline E. Peterson, Elaine B. Morrison et al. · 2021 · SSRN Electronic Journal
  90. Cryo-EM structure of endogenous Pfs230:Pfs48/45 complex with six antibodies reveals mechanisms of malaria transmission-blocking activity
    Ezra T. Bekkering, Randy Yoo, Sophia Hailemariam, Fabian Heide, Danton Ivanochko, Matthew J. Jackman, Nicholas I. Proellochs, Rianne Stoter, Geert‐Jan van Gemert, Ayana Maeda et al. · 2025 · Immunity
  91. Coronavirus vaccines get a biotech boost
    Amber Dance · 2020 · Nature
  92. Advanced Vaccine Design Strategies against SARS-CoV-2 and Emerging Variants
    Jianzhong Zhang, Yutian Xia, Xuan Liu, Gang Liu · 2023 · Bioengineering
  93. Respiratory syncytial virus
    Flor M. Muñoz, Janet A. Englund · 2019 · Elsevier eBooks
  94. Self-amplifying mRNA vaccines protect elderly BALB/c mice against a lethal respiratory syncytial virus infection
    Lulu Zuo, Qixing Liu, Ke Zhang, Lu Zhao, Siyu Lin, Yong Dai, Yun Sun, Yingwen Li, Pingping Zhang, Huyan Shen et al. · 2024 · Molecular Therapy
  95. DS2 designer pre-fusion F vaccine induces strong and protective antibody response against RSV infection
    Yiling Yang, Ruoke Wang, Fenglin Guo, Tian Zhao, Yuqing Lei, Qianqian Yang, Yige Zeng, Ziqing Yang, Tatchapon Ajavavarakula, Ruijie Tan et al. · 2024 · npj Vaccines
  96. Photoinduced Cleavage of Respiratory Syncytial Virus by Chiral Vanadium Trioxide Nanoparticles
    Baimei Shi, Xinxin Xu, Maozhong Sun, Yingcai Xiong, Jianjian Ji, Aihua Qu, Hua Kuang · 2025 · Advanced Materials
  97. Improved mRNA-based RSV vaccine with PreF forming enveloped virus-like particles
    Pengdi Chai, Yi Shi, Xiaoyan Li, Mengyao Yang, Xiafei Liu, Mei Liu, Junjie Yu, Xia Yin, Dongwei Li, Ke Li et al. · 2025 · npj Vaccines
  98. Host Immune Response to Respiratory Syncytial Virus Infection in Children
    Gang Chen, Xiuchang Ma, Jinhuan Wu, Yi Yan, Wenxian Qian, Apeng Chen, Changhua Yi, Man Tian · 2025 · Influenza and Other Respiratory Viruses
  99. Systematic computer-aided disulfide design as a general strategy to stabilize prefusion class I fusion proteins
    Karen J. Gonzalez, Kevin C. Yim, Jorge C. G. Blanco, Marina S. Boukhvalova, Eva‐Maria Strauch · 2024 · Frontiers in Immunology
  100. An mRNA-Based Respiratory Syncytial Virus Vaccine Elicits Strong Neutralizing Antibody Responses and Protects Rodents Without Vaccine-Associated Enhanced Respiratory Disease
    Jianglong Li, Haiyan Long, Shaoyi Chen, Zhendong Zhang, Shuang Li, Qi Liu, Jun Liu, Jiaru Cai, Liping Luo, Yucai Peng · 2025 · Vaccines